The des-fluoroquinolone BMS 284756 was active in vitro against all 151 clinical strains of Eikenella corrodens at a MIC of <0.25 g/ml and was comparable in activity to moxifloxacin and levofloxacin. The MIC at which 90% of the isolates were inhibited by penicillin G was 2 g/ml; MICs for 8.6% of the strains (13 of 151) were >4 g/ml, including for two beta-lactamase-producing isolates. Amoxicillin-clavulanate and ampicillin-sulbactam inhibited all strains at a MIC of <1 g/ml.Eikenella corrodens, a capnophilic, fastidious, slow-growing, gram-negative rod, has been increasingly implicated in a variety of infections associated with the human oral flora (1-2, 4-6). It is part of the normal oral microbiota recovered in approximately 60% of plaque samples (1, 7) and has been associated with human periodontitis (21). E. corrodens may also be found on the surface of the tongue, tonsils, and buccal mucosa and in saliva. Humans may harbor more than one clonal type of E. corrodens in the oral cavity; the significance of this is presently unknown.While little is known about the role of the virulence factors of E. corrodens in pathogenicity (1,19), common E. corrodensassociated infections include oral alveolar abscesses, parotitis, sinusitis, osteomyelitis of the mandible, bacteremia, and endocarditis following dental manipulation (4,12,17,22). A strong association between subgingival E. corrodens and Actinobacillus actinomycetemcomitans in juvenile periodontitis has also been suggested (16). A knowledgeable basis for therapeutic selection of appropriate antimicrobial agents is essential.Eikenella corrodens has a somewhat peculiar antimicrobial susceptibility pattern, being susceptible to penicillin but resistant to penicillinase-resistant penicillins such as dicloxacillin, erythromycin, other macrolides, clindamycin, metronidazole, and aminoglycosides (8, 9). The fluoroquinolones have been previously shown to be active against E. corrodens (10), but most have limited activity against anaerobic bacteria which are frequent copathogens in oral flora-based infections. The new des-fluoroquinolone BMS 284756 has been reported to have improved anaerobic activity (3,25). To see if BMS 284756 is of clinical utility in multibacterial oral infections, we studied its comparative in vitro activity against 151 clinical isolates of E. corrodens.The strains tested were previously isolated from human infections (respiratory and/or oral isolates, 54; human and animal bites, 29; soft-tissue wounds, 15; other sources, 49) and identified by standard criteria (11, 18). Isolates were gramnegative, capnophilic rods that were positive for oxidase, nitrate reductase, and ornithine decarboxlyase. Negative reactions were observed for catalase, urease, lysine decarboxylase, arginine dihydrolase, esculin hydrolysis, indole production, and acidification of carbohydrates. Susceptibility testing was performed as previously reported (8, 9). Brucella agar supplemented with hemin, vitamin K1, and laked sheep blood was the basal medium. There is no NCCLS referen...